XML 64 R43.htm IDEA: XBRL DOCUMENT v3.26.1
Financial Assets and Liabilities - Additional Information (Detail)
€ / shares in Units, $ / shares in Units, € in Thousands
 1 Months Ended 3 Months Ended
May 06, 2026
Sep. 03, 2024
USD ($)
Multiple
Sep. 30, 2024
EUR (€)
XBB
Sep. 30, 2024
USD ($)
XBB
Sep. 30, 2023
EUR (€)
Multiple
XBB
Sep. 30, 2023
USD ($)
Multiple
XBB
Mar. 31, 2022
EUR (€)
Mar. 31, 2022
USD ($)
Mar. 31, 2026
EUR (€)
Days
€ / shares
Mar. 31, 2026
USD ($)
$ / shares
Dec. 31, 2025
EUR (€)
€ / shares
Disclosure of detailed information about financial instruments [line items]                      
Derivative liabilities                 € 290,482   € 256,231
Carrying amount of royalty funding liabilities                 298,100    
Fair value of royalty funding liabilities                 € 302,700    
Share price | € / shares                 € 48.6   € 48.9
Royalty Pharma U.S. Skytrofa [member]                      
Disclosure of detailed information about financial instruments [line items]                      
Funding received in exchange of royalty payments | $           $ 150,000,000          
Funding received in exchange of royalty payments | $           150,000,000          
Net proceeds after deduting offering expenses         € 136,300 $ 146,300,000          
Net revenue from sales interest payment in percentage in exchange for funding         9.15% 9.15%          
Royalty payment beginning period         Jan. 01, 2025 Jan. 01, 2025          
Royalty payment ending period         Dec. 31, 2031 Dec. 31, 2031          
Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice as buyout amount | XBB         1.925 1.925          
Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice provided on or prior to period as buyout amount | XBB         1.65 1.65          
Royalty Pharma U.S. Skytrofa [member] | Bottom of range [member]                      
Disclosure of detailed information about financial instruments [line items]                      
Multiple of the purchase price were royalty payment will cease | Multiple         1.65 1.65          
Royalty Pharma U.S. Skytrofa [member] | Top of range [member]                      
Disclosure of detailed information about financial instruments [line items]                      
Multiple of the purchase price were royalty payment will cease | Multiple         1.925 1.925          
Royalty Pharma U.S. Yorvipath [member]                      
Disclosure of detailed information about financial instruments [line items]                      
Funding received in exchange of royalty payments | $   $ 150,000,000                  
Funding received in exchange of royalty payments | $       $ 150,000,000              
Net proceeds after deduting offering expenses     € 134,200 $ 148,200,000              
Net revenue from sales interest payment in percentage in exchange for funding   3.00%                  
Royalty payment ending period   Dec. 31, 2029                  
Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice as buyout amount | XBB     2 2              
Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice provided on or prior to period as buyout amount | XBB     1.65 1.65              
Royalty Pharma U.S. Yorvipath [member] | Bottom of range [member]                      
Disclosure of detailed information about financial instruments [line items]                      
Multiple of the purchase price were royalty payment will cease | Multiple   1.65                  
Royalty Pharma U.S. Yorvipath [member] | Top of range [member]                      
Disclosure of detailed information about financial instruments [line items]                      
Multiple of the purchase price were royalty payment will cease | Multiple   2                  
Historical volatility for shares, measurement input [member] | Derivatives [member]                      
Disclosure of detailed information about financial instruments [line items]                      
Percentage of reasonably possible increase in unobservable input, liabilities                 10.00% 10.00%  
Percentage of reasonably possible decrease in unobservable input, liabilities                 10.00% 10.00%  
Share Price Measurement Input [Member] | Derivatives [member]                      
Disclosure of detailed information about financial instruments [line items]                      
Increase decrease in derivative financial liabilities fair value                 € 57,600    
Percentage of reasonably possible increase in unobservable input, liabilities                 10.00% 10.00%  
Percentage of reasonably possible decrease in unobservable input, liabilities                 10.00% 10.00%  
Foreign Currency Conversion Option [Member]                      
Disclosure of detailed information about financial instruments [line items]                      
Increase decrease in derivative financial liabilities fair value                 € 12,500    
American depository shares [member]                      
Disclosure of detailed information about financial instruments [line items]                      
Conversion price per share | $ / shares                   $ 166.34  
Convertible Senior Notes [Member]                      
Disclosure of detailed information about financial instruments [line items]                      
Conversion rate per note | $ / shares                   $ 6.0118  
Principal amount | $               $ 575,000,000      
Borrowings redemption period                 April 7, 2025    
Borrowings condition for redemption                 but only if the last reported sale price per ADS exceeds 130% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related optional redemption notice; and (ii) the trading day immediately before the date the Company sends such notice.    
Borrowings threshold percentage of sale price per share for redemption                 130.00%    
Borrowings threshold trading days for redemption | Days                 20    
Borrowings threshold consecutive trading days for redemption | Days                 30    
Proceeds from issue of bonds, notes and debentures             € 503,300 $ 557,900,000      
Carrying amount of convertible notes                 € 448,200    
Fair Value of Convertible Notes                 € 448,400    
Borrowings, maturity             April 1, 2028 April 1, 2028      
Convertible Senior Notes [Member] | American depository shares [member]                      
Disclosure of detailed information about financial instruments [line items]                      
Principal amount | $                   $ 1,000  
Fixed interest rate [member] | Convertible Senior Notes [Member]                      
Disclosure of detailed information about financial instruments [line items]                      
Borrowings interest rate 2.25%             2.25% 2.25% 2.25%  
Events After Reporting Period [Member] | Convertible Senior Notes [Member]                      
Disclosure of detailed information about financial instruments [line items]                      
Borrowings interest rate 2.25%                    
Borrowings redemption period May 6, 2026                    
Borrowings, maturity 2028.